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Abstract
Background: The benefit of statin on the management of Type 2 Diabetes Mellitus (T2DM) among Chinese
patients in primary care is not clear nor fully implemented in clinical practice. This study aimed to evaluate and
quantify the benefit of statin on the overall cardiovascular risk and all-cause mortality in patients with T2DM.
Methods: Uncomplicated diabetic patients with baseline low-density-lipoprotein cholesterol (LDL-C) > 2.6 mmol/L
and without statin use before baseline in 2010 were followed-up for 5 years for cardiovascular disease (CVD) events
and all-cause mortality. Propensity score matching analysis was conducted to identify patients who were newly
prescribed statin at baseline and then compared to non-statin users with similar baseline characteristics. Subgroup
analysis was done within the statin group to detect any difference in outcomes between patients achieving target
LDL-C of <2.6 mmol/L and not. Multivariable Cox proportional hazards regression with adjustment of all baseline
covariates was used to evaluate the effect of statin on outcome events. Hazard ratio (HR) and its 95% confidence
intervals were reported.
Results: 10,104 pairs of diabetic patients were propensity score matched. Statin users had an extra drop of 1.
21 mmol/L in LDL-C than non-users. Statin group had a CVD incidence rate of 16.533 per 1000 person-years
whereas comparison group had 32.387 per 1000 person-years (HR: 0.458) during a median follow-up period of 50.
5 months. Statin group had a mortality rate of 8.138 deaths per 1000 person-years whereas comparison group had
19.603 deaths per 1000 person-years (HR: 0.378). For patients prescribed with statin, the HR was 0.491 for CVD and
0.487 for all-cause mortality if target of LDL-C < 2.6 mmol/L achieved compare to those not achieved.
Conclusions: Use of statin was associated with a significant decrease in CVD risk and all-cause mortality among
diabetic patients in primary care, and the risk reduction was most significant if the target of LDL-C less than 2.
6 mmol/L was achieved.
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Background
The global trend of aiming at reduction of the overall
cardiovascular risk in the management of diabetic pa-
tients makes the lipid-lowering class of drugs-statin one
of the commonly prescribed medications in the drug
regimen of patients diagnosed with Type 2 Diabetes
Mellitus (T2DM). Statin, with its main pharmacological
effect being lowering of the low density-lipoprotein chol-
esterol (LDL-C) level, also has the potential to lower tri-
glyceride and raise high-density-lipoprotein cholesterol,
and hence it was commonly used as the first-line oral
medication to lower lipid level and reduce the associated
cardiovascular risk. A LDL-C target of 2.6 mmol/L or
below is commonly set for patients with T2DM. Many
guidelines or practitioners view T2DM as a cardiovascu-
lar event equivalent, and suggest LDL-C level should be
lowered to below 1.8 mmol/L. Although lifestyle inter-
vention including diet and regular physical activity are
advocated for patients to control their hyperlipidemia,
the dramatic effect of statin on the drop of LDL-C and
the comparable few side-effects make statin a popular
option in the management of patients with T2DM. Many
Western studies had affirmed the benefit of statin on the
lipid-lowering effect and the reduction of cardiovascular
events. Meta-analysis showed that amongst patients
without established cardiovascular diseases but with car-
diovascular risk factors, statin use was associated with
significant improvement in survival and large reductions
in major cardiovascular events risks [1]. However, the
impact of statin on the overall management of T2DM in
Asian populations, including Chinese population is not
clear. Little evidence can be found on how the use of
statin can lower the cardiovascular risk and all-cause
mortality. This gap is imminently needed as the coverage
of statin in diabetic patients is lower comparable to
Western population. Chinese patients are reluctant to
use statin and one of the reasons is the fear of the po-
tential side-effect of liver impairment. Many Chinese pa-
tients have an excuse that they can eat more healthily
and do more exercise, so that they do not need to start
using lipid-lowering agent. However, what is observed is
that they cannot reach the lifestyle modification level
that may have the equivalent impact on improving their
lipid profile by lipid-lowering agent. Solidify the benefits
of lipid-lowering agent can give an option to the diabetic
patients and their doctors on how the lipid profile can
be improved. This study aimed to evaluate the benefit of
statin on the overall cardiovascular risk and all-cause
mortality in patients with T2DM, so that physicians
could have more evidence to discuss with their patients
regarding the use of statin in the management plan of
T2DM. The objectives of the study were to reveal the
hazard ratios of cardiovascular diseases and all-cause
mortality by comparing patients with T2DM taking
statin versus those not taking statin in the primary care
setting. This comparison was particularly meaningful in
primary care settings because uncomplicated diabetic
patients were encouraged to be taken care by primary
care physicians while diabetic patients with complica-
tions may need to be taken care by secondary or ter-
tiary care providers. If statin use could be shown being
able to prevent significantly CVD or related complica-
tions at primary care level, the need of secondary or
tertiary healthcare services can be greatly reduced, thus
saving the associated expensive medical cost at second-
ary or tertiary care level. In addition, the health-related
quality of life of the diabetic patients can also be main-




This retrospective cohort study included Chinese patients
with T2DM having their diabetes being followed-up in
public primary healthcare. The dataset was retrieved from
an evaluation of a large-scale local evaluation of diabetes
care [2]. Data were gathered through the administratives
from the central computerized database under the Hos-
pital Authority (HA), the largest government organization
in-charge of all public hospitals and out-patient clinics in
Hong Kong, between 1 January 2010 and 31 December
2010.
Adult Chinese (aged 18 years or above) bearing a
clinical diagnosis of T2DM, without prior CVD or liver
disease history, and having follow-up in primary care
clinics of HA between 1 January 2010 and 31 December
2010 were included in the study. The clinical diagnosis
of T2DM was identified using the International Classifi-
cation of Primary Care-2 (ICPC-2) code of ‘T90’ through
the administrative database of HA and the CVD identifi-
cation was described in the subsequent section. The
baselines for statin and comparison groups were defined
as the date of first prescription with statin and the first
attendance record in primary care clinics for DM follow-
up, respectively. Patients with new prescription of statin
at baseline were classified as statin group, and those with
prior statin prescription record before baseline, or with
LDL-C < 2.6 mmol/L at baseline, or stopped statin
within 1 year after baseline were excluded. Patients not
undertaking statin at or before baseline were classified
as comparison group, and were excluded if they had any
statin treatment within 1 year after baseline. Since there
was no standardized definition or protocol of lifestyle
changes in the care plan of diabetic patients, all diabetic
patients in both groups received lifestyle modification
advice and education upon their T2DM follow-up con-
sultation as usual.
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Exposures
Follow-up started at baseline and continued until a
switching to or addition of another anti-diabetic medica-
tion, the date of incidence of the first outcome event,
all-cause mortality, a censoring event or last contact
with any in-patient and out-patient services of HA as
censoring until the end of study on 30 November 2015.
Generally, the interval between follow-up consultations
for diabetic patients in HA general out-patient clinics
was from three to four months, and the supply of the
chronic medications (including statin) matches with the
follow-up interval. The prescription seldom exceeds a
maximum of 120 days’ drug supply. Patients with T2DM
who were not put on any chronic medications may have
a longer follow-up period but would not be more than
six months (180 days) usually. Thus, the censoring
events were 121 days of no drug prescription record for
statin group and 181 days of no attendance record in
out-patient clinics for comparison group.
Outcomes: Cardiovascular events and mortality
The outcomes of interest were events with one of the
following subtype diagnoses: 1) CVD event with one of
the following diagnoses: coronary heart disease (CHD),
stroke, or heart failure, 2) CHD, 3) stroke, 4) heart failure
and 5) all-cause mortality. The diagnosis of comorbidities
was identified by the diagnosis coding system of ICPC-2
and International Classification of Diseases, Ninth Edition,
Clinical Modification (ICD-9-CM).
The earliest date of diagnosis with ICPC-2 of K74 to
K76 or ICD-9-CM of 410.x, 411.x to 414.x, 798.x was
marked as the time of CHD (including ischaemic heart
disease, myocardial infarction, coronary death) or sudden
death event. The earliest date of diagnosis with ICPC-2 of
K77 or ICD-9-CM of 428.x was the time of heart failure
event. The earliest date of diagnosis with ICPC-2 of K89
to K91 or ICD-9-CM of 430.x to 438.x was the time of
stroke event (including fatal and non-fatal). All-cause
mortality was determined using the Hong Kong Death
Registry population data.
Baseline covariates
Baseline covariates of patients were categorized into four
branches: [1] socio-demographics, [2] clinical parame-
ters, disease characteristics and treatment modalities.
Socio-demographics of patients covered age, gender
and smoking status. Clinical parameters consisted of
haemoglobin A1c (HbA1c), systolic and diastolic blood
pressure (SBP & DBP), lipid profile [LDL-C and total
cholesterol to high-density lipoprotein-cholesterol ratio
(TC/HDL-C) and triglyceride (TG)] and body mass
index (BMI). Disease characteristics encompassed self-
reported T2DM duration, presence of chronic kidney
disease (indicated by baseline estimated glomerular
filtration rate (eGFR) < 60 ml/min/1.73m2), Charlson’s co-
morbidity index, hypertension (defined by the clinical
diagnosis with ICPC-2 code of “K86” or “K87”) and family
history of DM. Treatment modalities included the usages
of insulin, oral diabetic and anti-hypertensive drugs. All
laboratory assays were performed in accredited HA
laboratories by the College of American Pathologists, the
Hong Kong Accreditation Service or the National Associ-
ation of Testing Authorities, Australia.
Data analysis
Patients with similar baseline characteristics were selected
from statin and comparison groups by means of propen-
sity score matching (PSM) analysis. Propensity score mod-
elled the probability of statin using multivariable logistic
regression with the adjustment of all baseline covariates.
The propensity score mapping was made using a one-to-
one matching with the nearest neighbour, within 0.001
caliper and without replacement approach.
Baseline characteristics of demographics, clinical param-
eters, disease characteristics and treatment modalities
were summarized using descriptive statistics. Differences
in baseline characteristics between statin and comparison
groups were tested using independent t-tests for continu-
ous variables or chi-square tests for categorical variables.
The pre- and post- changes in clinical parameters (HbA1c,
SBP, DBP, LDL-C, TC/HDL-C ratio, TG and BMI) for
statin and comparison groups were examined using paired
t-tests separately and the difference in difference between
statin and comparison groups was evaluated using inde-
pendent t-tests.
The CVD incidence rate was estimated by an exact 95%
confidence interval (CI) based on a Poisson distribution
[3]. Kaplan-Meier survival curves were reported and log-
rank test compared the differences in survival rates
between groups. Multivariable Cox proportional hazards
regression with the adjustment of all baseline covariates
was used to evaluate the effect of statin group comparing
with comparison group on the outcome events. Hazard
ratio (HR) and its 95% CI was reported for each variable
within the regression models. The proportional hazards
assumption was assessed by examining plots of the scaled
Schoenfeld residuals against time for the predictors.
Presence of multi-collinearity was checked by examining
the variance inflation factor. Eventually, a sensitivity ana-
lysis was performed by excluding subjects with follow-up
period less than two years.
All significance tests were two-tailed. A p-value <0.05
was considered statistically significant. All statistical ana-
lyses were performed using STATA Version 13.0.
Results
Figure 1 summarizes the flow of subjects in the study.
Originally, there were 14,132 (16.1%) and 73,395 (83.9%)
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eligible subjects in statin and comparison groups under
the primary care of HA between 1 January 2010 and 31
December 2010, respectively. After the exclusion of
subjects having management changed within one year
from baseline and missing data of baseline covariates,
remaining subjects in statin and comparison groups
were 10,623 and 40,821, respectively. 10,104 subjects
from each group were successfully matched with each
other using propensity score algorithm, regarding to all
baseline characteristics.
Table 1 displays the baseline characteristics between
the two groups after matching. The two groups showed
no significant difference in terms of all baseline charac-
teristics after PSM. Table 2 compares the key clinical
parameters between baseline and post-programme for
both statin and comparison groups. All clinical parame-
ters showed an improvement for both groups. As indi-
cated by the difference in difference, statin group had
significant improvements in SBP, DBP, LDL-C, TC/
HDL-C ratio and triglyceride than the comparison
group after the programme.
Table 3 shows the number and incidence rates of all-
cause mortality and CVD events. Statin group had lower
incidence rates in all-cause mortality and CVD events
than the comparison group. During a median follow-up
period of 50.5 months, statin group had a CVD inci-
dence rate of 16.533 per 1000 person-years whereas
comparison group had 32.387 per 1000 person-years
(Number needed to treat (NNT) = 54). Similarly, statin
group had an incidence rate of 8.138 deaths per 1000
person-years whereas comparison group had 19.603
deaths per 1000 person-years (NNT = 51). Further
breakdown of the CVD events into CHD, stroke and
heart failure also showed consistent results as that of the
all-cause mortality and CVD events.
Multivariable Cox proportional hazard regressions
were performed on the dependent variables of all-cause
mortality and CVD event and results are tabulated in
Fig. 1 Flow chart of subjects matching and comparison. LDL-C Low Density Lipoprotein Cholesterol; CVD Cardiovascular Disease. * Matched
subjects with propensity score matching using factors including age, gender, smoking status, HbA1c, BP, LDL-C, TC/HDL-C ratio, triglyceride, BMI,
presence of chronic kidney disease, duration of DM, hypertension, family history of DM, use of anti-hypertensive drugs use of lipid lowering
agents and Charlson Index
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Age (Mean ± SD, n), year 64.80 ± 10.32 (10,104) 64.82 ± 11.19 (10,104) 0.889
Gender 0.743
Female 58.19% (5880) 58.42% (5903)
Male 41.81% (4224) 41.58% (4201)
Smoking Status 0.796
Non-smoker 89.96% (9090) 90.07% (9101)
Smoker 10.04% (1014) 9.93% (1003)
Clinical Parameters (Mean ± SD)
HbA1c, % 7.31 ± 1.28 (10,104) 7.30 ± 1.33 (10,104) 0.505
SBP, mmHg 134.98 ± 16.51 (10,104) 134.85 ± 16.88 (10,104) 0.580
DBP, mmHg 74.94 ± 9.92 (10,104) 74.91 ± 10.05 (10,104) 0.865
LDL-C, mmol/L 3.76 ± 0.63 (10,104) 3.75 ± 0.64 (10,104) 0.615
BMI, kg/m2 25.73 ± 3.88 (10,104) 25.79 ± 3.91 (10,104) 0.289
TC/ HDL-C Ratio 4.76 ± 1.11 (10,104) 4.76 ± 1.09 (10,104) 0.997
Triglyceride, mmol/L 1.61 ± 0.79 (10,104) 1.62 ± 0.86 (10,104) 0.600
Disease Characteristics (%, n)
Duration of DM (Mean ± SD), years 7.11 ± 6.38 (10,104) 7.10 ± 6.25 (10,104) 0.881
Presence of Chronic Kidney Disease (%, n) 4.13% (417) 3.96% (400) 0.544
Charlson’s Index (Mean ± SD) 3.95 ± 1.05 (10,104) 3.96 ± 1.12 (10,104) 0.496
Hypertension 75.81% (7660) 75.93% (7672) 0.844
Family History of DM 46.61% (4709) 47.01% (4750) 0.563
Treatment Modalities (%, n)
Use of Insulin 1.39% (140) 1.44% (145) 0.765
Use of Oral Diabetic Drugs 88.08% (8900) 87.91% (8882) 0.697
Use of Anti-Hypertensive Drugs 78.66% (7948) 79.05% (7987) 0.502
HbA1c Haemoglobin A1c, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, LDL-C Low Density Lipoprotein - Cholesterol, BMI Body Mass Index, TC Total
Cholesterol, HDL-C High Density Lipoprotein - Cholesterol, DM Diabetes Mellitus
*Significant with p-value <0.05 by chi-square test or t-test as appropriate
Table 2 Clinical parameter comparisons between baseline and post
Clinical Parameters
(Mean ± SD)
Statin Group Paired Diff.a
(N = 10,104)
Comparison Group Paired Diff.a
(N = 10,104)
Diff. in diff.
(Statin Group - Comparison Group)
P-value
HbA1c, % −0.18 ± 1.31 −0.21 ± 1.29 0.02 0.223
SBP, mmHg −5.31 ± 19.81 −3.28 ± 19.20 −2.03 < 0.001*
DBP, mmHg −4.06 ± 10.89 −1.96 ± 10.49 −2.09 < 0.001*
LDL-C, mmol/L −1.47 ± 0.79 −0.26 ± 0.64 −1.21 < 0.001*
TC/ HDL-C Ratio −1.39 ± 0.99 −0.40 ± 1.04 −1.00 < 0.001*
Triglyceride, mmol/L −0.25 ± 0.75 −0.12 ± 0.79 −0.14 < 0.001*
BMI, kg/m2 −0.25 ± 1.81 −0.26 ± 1.62 0.01 0.699
HbA1c Haemoglobin A1c, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, LDL-C Low Density Lipoprotein - Cholesterol, TC Total Cholesterol, HDL-C High
Density Lipoprotein - Cholesterol, BMI Body Mass Index
*Significant with p-value <0.05 by independent t-test
aPaired difference (Post - baseline)
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Table 4. The variance inflation factors ranged from 1 to
5.08, which indicated no violation of proportional hazard
and absence of multi-collinearity. Observed random
scattered points from the scaled Schoenfeld residual
plots indicated the proportional hazard assumption was
satisfied. There was a 62.2% risk reduction of all-cause
mortality in statin group compared to comparison group
and the difference in their survival time was highly sig-
nificant (P < 0.001) by log-rank test. Moreover, in terms
of the incidence of CVD events (including CHD, stroke
and heart failure), patients in statin group had around
55–60% risk reduction when compared to the compari-
son group. Log-rank test also suggested that there were
significant differences (P < 0.001) in the survival time of
all CVD events between the two groups. Sensitivity ana-
lysis was conducted with the exclusion of subjects whose
follow-up periods were less than two years and similar
results were obtained.
Sub-group analysis was performed on patients started
with statin to differentiate patients achieving target of
LDL-C < 2.6 mmol/L and those who did not (Table 5).
Diabetic patients who were put on statin had HR of
0.444 to 0.553 for CVD and all-cause mortality if they
achieved the target of LDL-C < 2.6 mmol/L.
Discussion
This study is by far the latest analysis on a large popula-
tion scale to quantify the beneficial impact of using
statin on diabetic patients under the primary care, by
comparing directly the different clinical parameters and
cardiovascular complications and all-cause mortality.
Our study was coherent with other Western trials that
greater LDL-C reduction led to greater CV risk reduc-
tion [4, 5]. Statin is well known for lowering LDL-C.
This study manifested that patients with T2DM who
were prescribed with statin for their associated hyperlip-
idemia had significant lipid-lowering effects (in terms of
decreasing LDL-C, TC/HDL-C, and TG) in Chinese










Rate Estimate 95% CI*
Statin Group (N = 10,104)
CVD 789 7.81% 16.533 (15.400, 17.728) 47,722.2
CHD 382 3.78% 7.902 (7.129, 8.736) 48,341.8
Stroke 312 3.09% 6.458 (5.761, 7.216) 48,313.9
Heart Failure 196 1.94% 4.036 (3.491, 4.643) 48,560.5
All-cause Mortality 397 3.93% 8.138 (7.357, 8.980) 48,781.3
Comparison Group (N = 10,104)
CVD 977 9.67% 32.387 (30.387, 34.483) 30,166.8
CHD 476 4.71% 15.691 (14.313, 17.166) 30,336.1
Stroke 410 4.06% 13.534 (12.256, 14.910) 30,293.0
Heart Failure 240 2.38% 7.913 (6.943, 8.980) 30,331.3
All-cause Mortality 596 5.90% 19.603 (18.061, 21.242) 30,402.8
CVD Cardiovascular Disease, CHD Coronary Heart Disease, DM Diabetes
Mellitus, CI Confidence Interval
*The 95% CI was constructed based on Poisson distribution
Table 4 Multivariable Cox proportional hazard regression on
the dependent variables of CVD event and all-cause mortality
Statin Group Comparing with Comparison Group
HRa 95%CI P-value
Main Analysis (N = 20,208)
CVD 0.458 (0.415,0.504) <0.001*
CHD 0.436 (0.380,0.502) <0.001*
Heart Failure 0.488 (0.402,0.593) <0.001*
Stroke 0.429 (0.368,0.499) <0.001*
All-cause Mortality 0.378 (0.331,0.431) <0.001*
Sensitivity Analysis (N = 15,776)
CVD 0.522 (0.462,0.589) <0.001*
CHD 0.467 (0.390,0.559) <0.001*
Heart Failure 0.581 (0.454,0.742) <0.001*
Stroke 0.516 (0.428,0.622) <0.001*
All-cause Mortality 0.382 (0.325,0.450) <0.001*
Sensitivity analysis: exclude subjects with follow-up period less than 2 years
CVD Cardiovascular Disease, CHD Coronary Heart Disease, HR Hazard Ratio, CI
Confidence Interval
*p-value <0.05
aHazard ratios were adjusted by age, gender, smoking status, haemoglobin
A1c, systolic blood pressure, diastolic blood pressure, triglyceride, low density
liporotein-cholesterol, body mass index, total cholesterol-to-high density
lipoprotein-cholesterol ratio, presence of chronic kidney disease, duration of
diabetes mellitus, Charlson Index, diagnosed hypertension, family history of
diabetes mellitus and usages of insulin, oral and anti-hypertensive drugs index
at baseline
Table 5 Multivariable Cox proportional hazard regression on
the dependent variables of CVD event and all-cause mortality
within statin group
Post LDL-C < 2.6 mmol/L (n = 7641) comparing
with post LDL-C ≥ 2.6 mmol/L (n = 2463)
HRa 95%CI P-value
Main Analysis (N = 10,104)
CVD 0.491 (0.422,0.571) <0.001*
CHD 0.477 (0.385,0.591) <0.001*
Heart Failure 0.444 (0.329,0.600) <0.001*
Stroke 0.553 (0.433,0.708) <0.001*
All-cause Mortality 0.487 (0.393,0.602) <0.001*
LDL-C Low Density Lipoprotein-Cholesterol, CVD Cardiovascular Disease, CHD
Coronary Heart Disease
*p-value <0.05
aHazard ratios were adjusted by age, gender, smoking status, haemoglobin
A1c, systolic blood pressure, diastolic blood pressure, triglyceride, low density
liporotein-cholesterol, body mass index, total cholesterol-to-high density
lipoprotein-cholesterol ratio, presence of chronic kidney disease, duration of
diabetes mellitus, Charlson Index, diagnosed hypertension, family history of
diabetes mellitus and usages of insulin, oral and anti-hypertensive drugs index
at baseline
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diabetic population. Our study confirmed that further to
lipid-lowering effect, use of statin itself was associated
with risk reduction of suffering from various CVD com-
plications and all-cause mortality. Statin approximately
halved the CVD risk, and reduced all-cause mortality by
more than 60%. Our sub-group analysis showed that if
patients undertook statin and had achieved the target of
LDL-C < 2.6 mmol/L at the same time, the risk reduc-
tion was much greater. Apart from its lipid-lowering ef-
fect, statin may reduce the complications through other
mechanisms like ameliorating endothelial function,,
keeping plaque stability, abating thrombus formation,
and modulating inflammatory responses, etc. [6]. The
pleiotropic effects of statins on reducing CVD events
included amelioration of endothelial dysfunction, nor-
malized vasomotion, enhanced nitric oxide bioavailabil-
ity, antioxidant effects, anti-inflammatory effects, plaque
stabilization, stimulation of endothelial progenitor cell
recruitment, immunomodulation, and inhibition of myo-
cardial hypertrophy [7]. The beneficial pleiotropic effect
of statin could account for the CV risk drop even in
those patients prescribed with statin but did not achieve
the LDL-C target. However, the risk reduction effect of
statin is more prominent if the LDL-C can be kept to an
optimal level. This leads to the discussion of adding
other newer lipid-lowering agents which act on different
mechanisms like ezetimibe or PCSK9 Inhibitors [8].
Statin is advocated and used as the first-line lipid-lower-
ing medication globally for hyperlipidemia (particularly
hypercholesterolaemia) unless contraindicated. One chal-
lenging clinical decision family physicians or general prac-
titioners have to make is to decide if and when a
diabetic patient with hyperlipidemia should start pre-
scribing statin, particularly at the early stage of man-
agement of their diabetes in order to reduce the overall
cardiovascular risk and complications. Findings from
this study provide more evidence and help family physi-
cians or general practitioners to make a shared decision
with their diabetic patients.
At baseline, the number of diabetic patients with
hyperlipidemia who were not taking statin was 5 times
of those taking statin. This was similar to other studies
which showed the inadequate use of statin and the sub-
optimal control of LDL-C [9, 10]. For example, less than
half of the US adults with elevated LDL-C levels received
treatment to lower their cholesterol, and less than 33%
of patients achieved their target LDL-C levels despite
using currently available treatments [10]. It was common
for Chinese diabetic patients to keep observing their ele-
vated LDL-C instead of starting statin. They had the
health belief that LDL-C level would go down if they eat
more healthily and do some more exercise, which they
usually over-estimate their ability to comply with the re-
quired level of life style modifications. On the other
hand, some physicians may reinforce this “non-pharma-
cological” approach of management, hoping to motivate
their patients more adhere to healthy lifestyle modifica-
tions through diet regulations and regular exercise
pattern. Patients’ reluctance to use lipid-lowering drugs
mostly originated from the underlying fear of the
potential harmful effects on their liver, and the need to
take the lipid-lowering drugs life-long [11]. Drug com-
pliance would also be an issue because most of them
experienced no hyperlipidemia-related symptoms, and
they did not have objective measurements of their lipid
level frequently like that of the home blood glucose or
home blood pressure monitoring. They would also like
to try alternative ways including herbs to lower their
lipid-level [11, 12]. Some patients may turn to alterna-
tive medicine or Chinese medicine practitioners, which
is not uncommon in Chinese community as traditional
Chinese medicine has its own school of theory and
management on hyperlipidemia [12]. A recent review
suggested that the concern of side-effects of statin,
which was still an underlying reason of the under-use
of statin amongst patients with high CVD risk like diabetic
patients, may be exaggerated, and that an informed
decision on statin use for CVD events prevention should
be advocated [13]. The financial influence on the statin
prescription in our study population was negligible as the
consultation fee was HKD 45 [USD 5.78] only under pub-
lic primary care without additional drug fee for statin
prescription.
While the concept of lifestyle modification is rather
abstract, more and more studies are now suggesting
that the association between diet and hyperlipidemia
may not be that strong [9]. Some patients who claim to
have very low level of fat intake in their diet are still
found to have hyperlipidemia. There are some other
possible factors like genetic or comorbidities having a
stronger association with hyperlipidemia, and hence
diet control alone may not be helpful. More studies
pointed that the circulating cholesterol was indeed
manufactured by liver rather than absorbed through
diet [14]. Blocking the hepatic synthesis of cholesterol
may have a more promising outcome of reducing LDL-
C and subsequent CVD risk and mortality than diet
modification.
The magnitude of LDL-C reduction from our study was
comparable to studies from other regions [7], suggesting
that statin worked well on Chinese patients in reducing
LDL-C. Comparison group had shorter median follow-up
period (30.5 months) than the statin group (63.5 months)
which suggested that comparison group had a higher
probability of having changes in their condition (either the
control of hyperlipidemia or an event occurrence) that
warrants a change of their management of hyperlipidemia.
There was one local prospective cohort study in 1996 to
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2005 on lipid control and use of lipid-lowering medica-
tions for prevention of cardiovascular events in Chinese
T2DM patients [15]. It showed that statins use was associ-
ated with lower CVD risk with a HR 0.66 (0.50–0.88).
There were several potential reasons why our HR
(0.458 to 0.522) was lower than that. Our study sample
was larger, with more female patients, fewer smokers,
lower systolic BP, lower baseline HbA1c, and higher
baseline LDL-C (more room for LDL-C reduction). All
these can contribute to the lower HR in our study than
the previous study.
After controlling the severity of hyperlipidemia (as in-
dicated by LDL-C) and other factors, a patient on statin
had 62.2% and 54.2% lower risk of having all-cause
mortality and any of the CVD event when compared to
a patient not on statin. Such risk reductions may be
partially attributed by the concurrent reduction in SBP,
DBP, TC/HDL-C, and TG. With reference to the United
Kingdom prospective diabetes study (UKPDS) and a
meta-analysis from Cholesterol Treatment Trialists’
(CTT) Collaboration in which every 1 mmol/L reduc-
tion in LDL-C was associated with risk reduction of
CVD by 22%, stroke by 21%, CHD by 12% and all-cause
mortality by 9% [16, 17], our study revealed that diabetic
patients with statin use may well have a risk reduction in
CVD, stroke, CHD and all-cause mortality by 54%, 57%,
56% and 62%, respectively, when compared to statin
non-users.
The latest 2016 ESC/EAS Guidelines for the Manage-
ment of dyslipidemias recommends patients with high
CV risk (including diabetic patients), an LDL-C goal of
<2.6 mmol/L, or a reduction by at least 50% if the base-
line LDL-C is between 2.6 and 5.2 mmol/L [18]. The
comparison of our matched cohort showed that the sta-
tin group had a 39% reduction while the non-statin
comparison group had only 6.9% reduction in LDL-C.
Further studies are needed to take into account the
dosage of the statin to see if the newly recommended
50% reduction of LDL-C is applicable to Asian popula-
tion, and comparing those having at least 50% reduc-
tion in LDL-C to those who cannot on the subsequent
actual reduction in CVD complications or all-cause
mortality. However, our current finding of a 39% reduc-
tion in LDL-C level in diabetic patients using statin is
still encouraging.
With reference to the overall significant beneficial po-
tential of statin in the management of hyperlipidemia
and reduction in the cardiovascular risk and all-cause
mortality in diabetic patients, family doctors or general
practitioners should discuss with their patients in details
about the role of lipid-lowering medications in their
long-term management plan. In the interim, the role of
lifestyle modifications, including healthy diet, regular
exercise, and weight control, are equally important as
patients with chronic diseases are now encouraged
towards being more self-empowered and self-enabled
[19]. Nonetheless, any statin-related side-effects such as
liver impairment or allergic reaction should be alerted.
Strengths and limitations of the study
The study sample size was comparatively large. Compari-
son was done on propensity-score matched subjects to
eliminate any influence from other confounding factors
like age, severity of hyperlipidemia and diabetes mellitus
at baseline, etc. Sensitivity analysis was performed in
addition to full analysis to try to reduce any potential bias.
As most findings were consistent from both full cohort
with complete case and propensity score-matched cohort
analytical approaches, stain was strongly suggested to be
beneficial to diabetic patients with hyperlipidemia regard-
ing their clinical parameters and outcomes.
There are a few weaknesses in our study. Firstly, five
years may not be long enough for some cases of
cardiovascular complications or mortality to develop. A
longer period of follow-up can help to confirm if long-
term use of statin is still associated with lower cardio-
vascular risk or all-cause mortality. Secondly, details on
the use of statin including the exact dosage of statin
taken by each individual patient, were not available.
Drug compliance to statin could not be assessed in our
study. However, we performed the within group ana-
lysis by comparing patients achieved LDL-C target with
those did not within the statin group. We assumed that
those patients prescribed with statin and achieved LDL-
C target would have good drug compliance while poor
drug compliance may be one of the reasons for patients
prescribed with statin but the LDL-C target was not
achieved. The drawbacks of using statin, including side-
effects or intolerance had not been taken into account
for analysis. Also, the extent of lifestyle modifications of
the patients had not been recorded and thus could not be
taken into consideration of its effect on the improvement
in the lipid profile and the subsequent cardiovascular risk
reduction.
Conclusions
Hyperlipidemia with LDL-C ≥ 2.6 mmol/L was prevalent
in diabetic patients. Statin was still under prescribed. Use
of statin was associated with a significant decrease in
cardiovascular disease risk and all-cause mortality in dia-
betic patients, and the risk reduction was more outstand-
ing if the statin could help the diabetic patients to achieve
their target LDL-C of less than 2.6 mmol/L.
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